CHAPTER 7

MODERN INNOVATIONS IN TRANSDERMAL DELIVERY

Transdermal drug delivery has experienced astounding developments in the recent years due to the requirement of non-invasive, controlled, and patient-centered therapeutic systems. Conventional transdermal formulation, in terms of its efficacy, is effective with small lipophilic molecules and is limited upon the ability to deliver larger biomolecules, peptides, proteins, and hormones because the stratum corneum is a formidable barrier. To resolve these issues, in the recent past, a number of innovative tools have been integrated with sophisticated technologies, which include microneedles, nanocarriers, patches with smart biosensors, and physical enhancement techniques, including thermal ablation, sonophoresis, and electroporation. Such methods do not only increase the skin permeability and drug bioavailability, but also provide a capacity of the precise, sustained, and site-specific drug delivery, decreasing systemic side effects and enhancing patient compliance. Moreover, the integration of transdermal systems with digital health technologies such as internet-of-thing-enabled wearable devices, has brought about the prospect of real-time monitoring, feedback-controlled dosing, and personalised therapy as a groundbreaking step towards intelligent, adaptive drug delivery. This chapter discusses these advanced strategies, including their mechanisms, technological design, clinical use, and case studies, especially the use of transdermal delivery of insulin and hormones, which are considered as the potential of modern transdermal platforms to provide a safer, more convenient, and highly effective alternative to the invasive dimensions of their administration.

7.1 Microneedles and Nanocarriers for Enhanced Permeability

During the last few years, extraordinary breakthroughs have been experienced in the sphere of transdermal drug delivery because the objective of most therapeutic systems is non-invasive, controlled, and patient-oriented. Although useful with small and lipophilic molecules, traditional transdermal formulations have been limited in terms of their ability to deliver larger biomolecules, and protein, and hormonal molecules, because of the daunting barrier posed by the stratum corneum. The innovative solutions to these dilemmas are the incorporation of new technologies including microneedles, nanocarriers, physical enhancement using thermal ablation, sonophoresis, electroporation, and a patch-type bio sensor with intelligent biosensors. Not only does these methodologies improve skin permeability and drug bioavailability, but also allow controlled, sustained, and site-specific release of drugs to essentially reduce side effects of the systemic aspects of the drugs, and increase adherence in patients. In addition, the merging of transdermal systems with digital health technologies such as wearable devices connected to the Internet of Things have brought the option of real-time monitoring and feedback-controlled dosing and personalized therapy, giving a paradigm shift in intelligent, adaptive drug delivery. This chapter discusses these ultra-modern strategies including their mechanisms, technology design, clinical application and case studies, especially discussing the use of transdermal delivery of insulin and hormones that demonstrate the potential of the modern transdermal platform to substitute invasive routes of administration with safer and more convenient and highly-effective delivery methods.

Figure 7: Innovations in transdermal drug delivery system

7.1.1 Microneedle Technology: Design, Types, and Mechanism of Action

One of the best strategies to increase the use of transdermal drug delivery is the use of Julius van der waals force in relation to Microneedle technology that does not produce pain or tissue damage. Microneedles (microscopic projections, usually ranging between 50 and 900 0 m in length) are punctures of stratum corneum that create temporary microchannels that enable the diffusion of drugs toward the deep strata of skin. They are designed to go around the dominant protective layer, but not stimulate the nerves or blood vessels on the skin of the area, making the administration of the drug painless and with the least invasive procedure.

Microneedles can be of several types, and have different structural and functional properties:

·       Solid Microneedles: These are used in creating temporary micro-channels prior to the application of a topical formulation or patch to increase the passive diffusion of the drug.

·       Coated Microneedles: The drug can be coated on the (needle) surface and dissolves quickly when inserted into the skin which gives a rapid action onset.

·       Dissolving Microneedles: Comprising of biodegradable polymers or sugars, which entrap the drug in their structure, which dissolves fully releasing the cargo into the skin without leaving behind sharp waste.

·       Microneedles: Hydrogel-forming: Controllable and sustained release over time of drugs Interstitial fluid absorbing and swelling to create a gel-like network.

Microneedle fabrication materials are made of silicon, stainless steel, titanium, biodegradable and polyvinylpyrrolidone, polyvinylpyrrolidone (PVP) and hyaluronic acid. The material used affects mechanical strength, dissolution rate and biocompatibility of the device. Microneedles have the capability of being integrated into self-administrable patch systems and administer consistent and reproducible drug doses.

In general, microneedle technology is a major improvement of patient-centred drug delivery offering a non-invasive alternative to injections in vaccines, insulin and peptide-based therapeutics and allowing tight control over drug release kinetics and systemic absorption.

7.1.2 Nanocarrier-Based Delivery Systems: Liposomes, Niosomes, and Polymeric Nanoparticles

One of the most recent drug delivery methods, nanocarrier-based transdermal systems, is based on the idea that nanoscale vehicles (the typical size of a vehicle is 10 to 1000 nanometers) will augment the delivery of therapeutic agents across the imposing skin barrier. The mechanisms of action of these nanocarriers are encapsulation, adsorption or chemical conjugation of drugs which in combination enhances solubility and stability of the drugs besides enzymatic degradation and chemical instability in the skin or systemic circulation that normally happens when drugs are used orally. Researchers can also modify the nanocarriers by designing particle size, surface charge, hydrophobicity, and composition with in vivo care and precision to influence the nanocarriers to provide controlled and sustained drug delivery, which would time-sustain therapeutic plasma levels.

In addition, nanocarriers can be programmed to target a site, which allows the drug to concentrate on specific areas of the tissues or enable it to be absorbed by the body system with minimal amounts to off-target action. The most common types of nanocarriers include liposomes, which are phospholipid-based vesicles that can entrap both hydrophilic and lipophilic drugs; niosomes, which are non-ionic surfactant vesicles that are more stable; solid lipid nanoparticles, which can provide a solid structure to entrap lipophilic drugs that is capable of controlled release; and polymeric nanoparticles, which can be functionalized to deliver drugs in a targeted and stimuli-responsive manner. Through a combination of these nanotechnologies and transdermal systems, these molecules can be effectively, safely, and non-invasively delivered: small drugs, peptides, proteins, and vaccines. Finally, transdermal delivery using nanocarriers increases bioavailability of drugs, therapeutic efficacy and increases the variety of drugs that can be given orally.

Several types of nanocarriers are commonly used in transdermal applications:

·       Liposomes: Liposomes are spherical vesicles made of phospholipid bilayers with the ability to shuttle the hydrophilic and lipophilic drugs within them. They dissolve into the lipid matrix of the stratum corneum, which increases the penetration of the drugs. Modifications to give better deformability and penetration into the skin include the use of ethosomes and transfersomes.

·       Niosomes: Surveys of liposomes, then more affordable and stable; they are non-ionic surfactants-based. They increase the permeation of not only small molecules but also big molecules and increase the stability of drugs and decrease irritation.

·       Polymeric Nanoparticles: These nanoparticles are made of biodegradable polymers, e.g. PLGA or chitosan, which guarantees controlled and sustained release of a drug. Their tunable nature enables them to accommodate a large range of drugs such as peptides, proteins, and those that are not soluble.

Nanocarriers improve permeation via a variety of mechanisms- by intermolecular interaction with skin lipids, drugs increase their thermal dynamic activity, or simply act as reservoirs to ensure a high concentration gradient across the skin. They can also be delivered using their nanoscale size to take advantage of an appendageal pathway (hair follicles and sweat ducts) or even temporarily destabilize the lipid bi-layer to be addressed.

Nanocarriers, as a collective, are beneficial in the contemporary method of transdermal drug delivery, as it provides a platform where therapeutic molecules can be released with the highest level of precision, sustained, and targeted release, aiding in decreasing the frequency of dosage administration and decreasing side effects which happen in the systemic environment. Their ability to be used together with microneedle assisting delivery is added to their effectiveness, with next-generation, patient-friendly transdermal systems being developed.

7.2 Smart Transdermal Patches with Biosensors

The combination of transdermal technology into drug delivery and biosensing, wearable electronics, and digital health systems has brought about a new dawn of smart transdermal patches which is a pivotal development on the old passive systems. In comparison to the traditional patches, which deliver the drugs at a constant fixed rate regardless of the specific needs of the individual patient, such intelligent systems have inbuilt biosensors which are capable of measuring and identifying vital physiological parameters in real time. With constant readings of the biomarkers like blood glucose, lactate, body temperature, pH, or disease-related specific indicators, smart patches can dynamically regulate the rate of drugs release according to the direct therapeutic needs of their patients. This reactive mechanism helps to achieve accurate and individual dosage, eliminating under- or overdosing risks, and minimizing the possible side effects of the systemic drug variability. Moreover, the inclusion of wearable technologies and wireless connectivity will support easy communications with mobile applications, cloud infrastructures or health monitors where clinicians can be used to schedule treatment remotely, track adherence and streamline treatment based on the data. Altogether, these breakthroughs not only improve the effectiveness and safety of treatment but also enable patients to actively participate in their health, which is a paradigm shift toward personalized, real-time, and adaptive healthcare, in which the training allows the treatment to be adjusted according to the current dynamism of the physiological state of the body.

7.2.1 Integration of Biosensors for Real-Time Monitoring and Feedback Control

Transdermal patches with biosensors are sensor-based patches used to retrieve real-time, self-administered therapy involved in drugs delivery. A biosensor is the device that scans certain biological signals (i.e. glucose level, sweat pH, and the skin temperature) and transforms this record into electrical impulses. Embedded microcontrollers interpret these signals and adjust the drug delivery rate or schedule based on the physiological conditions of the body at the point of time.

As an example, enzymatic biosensors identify high glucose levels in interstitial fluid, marked with insulin receptors, and are used in glucose responsive insulin patches. Increased glucose levels cause the biosensor to activate controlled dissolution of a polymeric material or a microvalve releasing insulin in proportion until normal levels of glucose are reestablished. Equally, infection-induced alterations in the acidity of the skin could be detected by the pH-sensitive sensor and then antimicrobial agents could be released, whereas temperature changes in the skin could be detected by temperature sensors and used to release pain-relief drugs, especially in case of local inflammation or fever.

These systems usually include, as their core elements:

•                Element of recognition (enzymes, antibodies or aptamers), which contact target analytes selectively.

•                Electrochemical, optical, or piezoelectric transducers which convert biochemical signals into electronic outputs which can be measured.

•                Feedback circuits or microprocessors that analyze the data and control the delivery of drugs in a closed-loop way.

The feedback-based delivery approach provides the maximum treatment efficacy, neurotoxicity, and adjusts to the principles of precision medicine. Moreover, biosensor-based patches make patients more comfortable as they do not require invasive skills, such as finger-prick glucose tests, as a monitoring technique, which increases compliance and comfort.

7.2.2 Internet of Things (IoT) and Wearable Connectivity in Smart Patches

Internet of Things (IoT) technology integration has transformed the operation of smart transdermal patches and turned them into complete access, wearable therapeutic platforms. IoT-based patches will be provided with wireless communication sensors, including BLT Low Energy (BLE), NFC, or Wi-Fi that will relay physiological and dosage data in real-time to other computing devices, such as smartphones, tablets, or health monitoring systems.

Such interconnectedness allows medical professionals to monitor a remote patient and make prompt interventions and therapy changes without having to visit the hospital. An example of this case is a patient with a smart insulin patch, whose glucose patterns can automatically be uploaded to a health platform based on the cloud, where they can be analyzed by algorithms about potential issues and reported either to the patient or the physician. By enabling personalized control of the therapy and early identification of deviations, this type of system makes the treatment much safer and more effective.

There are also smart patches that feature mobile applications to interact with the user and present data visualization and reminders, as well as features of compliance tracking. This interactive model increases the involvement of the user and will guarantee the maintenance of adherence to treatment. Moreover, the machine learning algorithms will be able to process the gathered biosensor records and forecast the trends in the future or the optimal dosage control of a specific patient.

Smart patches can be seen under the structure of IoT, and this includes:

•                Patches which monitor glucose by transmitting the levels in real time to smartphone applications.

•                The patches might also be used to track the heart rate and ECG signals and administer antiarrhythmic medications cardiac patches.

•                Pain management patches, which control analgesic discharge according to body temperature and activity.

Smart transdermal patches, a combination of biosensors, data analytics, and IoT connectivity, is an example of what the future of wearable precision therapeutics will look like: diagnosis, monitoring, and treatment are happening concurrently, and all of it on a connected and intelligent biomedical device.

7.3 Thermal Ablation, Sonophoresis, and Electroporation

The outer layer of the skin, which is the stratum corneum, serves as a very effective and discriminating barrier, allowing entry of most of the exogenous substances but keeping water and electrolytes in. This is because it has tightly packed keratinized cells in a lipid matrix rendering it very resistant to large, hydrophilic or charged molecules which causes a serious challenge to transdermal drug delivery. In order to overcome this shortcoming, investigators have come up with a number of physical enhancement methods used to alter temporarily and safely the barrier properties of the skin that enable the therapeutic agent to migrate more efficiently into deeper tissues without causing permanent tissue injury. Of these methods, thermal ablation, sonophoresis, and electroporation have become among the most promising methods because each of them uses a specific energy source to promote the drug transport.

In thermal ablation, a controlled heat is applied to the stratum corneum to form microscopic channels to enhance the permeability of both the small molecules and the macromolecules. Sonophoresis uses ultrasonic waves as a means of breaking lipid packing, improving the diffusion of molecules, and improving drug flux through the skin. Electroporation, in contrast, uses short and large voltage electric pulses to cause transient holes to the lipid bilayers to allow rapid passage of negatively charged and large molecules. Such novel approaches have broadened the therapeutic capabilities of transdermal systems since it is now possible to administer peptides, proteins, vaccines, and other high-weight drugs, which were previously limited to injection delivery. The efficacy applied in combination with patient-friendliness and painless administration, these methods are changing transdermal drug delivery, increasing adherence, and creating new opportunities in long-term and chronic therapies.

7.3.1 Physical Enhancement Mechanisms and Technological Advances

Thermal ablation, sonophoresis, and electroporation each employ distinct physical principles to disrupt the stratum corneum and create transient pathways for drug diffusion.

• Thermal Ablation:

In this procedure, brief medium intensity heat pulses are applied to the skin surface and vaporize or denature protein and lipid constituents of stratum corneum, producing microscopic pores or microchannels. The resulting microchannels can be permeated by the drugs and in particular the hydrophilic molecules and acromolecules through the otherwise impermeable barrier. Devices like laser-based systems and radiofrequency (RF) microheaters are usually utilized in this. Recent developments in technology aim at having precise temperature control, so as to have localized ablation, as well as without harming deep-lying tissues. It has been efficiently applied to treat thermal ablation of insulin, vaccines and small peptides.

• Sonophoresis (Ultrasound-Enhanced Delivery):

The ultrasound waves operated at sonophoresis increase drug permeation through the skin by using ultrasound waves of between 20 kHz and 10 MHz. A purely mechanical action that has been shown to occur is the acoustic cavitation, whereby the microscopic gas bubbles vibrate and implode within the lipids matrix of the skin causing temporary disruption to the lipid bi-layers. This is a mechanical perturbation that enhances the diffusivity of drug molecules. Also, localized heating and fluid convection due to ultrasound waves contribute to the further movement of hydrophilic compounds. More recent developments are low-frequency sonophoresis and systems in which ultrasound is used together with microneedles or iontophoresis in a synergistic manner.

• Electroporation:

Electroporation is the use of transient aqueous pores in the lipid domains of the stratum corneum through the use of short and high-voltage electrical pulses to the skin. These pores heighten the permeability of the skin, and consequently the penetrations of charged and large molecules become effective. The pores naturally reclose several minutes following the withdrawal of the electrical stimulus. Technology has improved to the current wearable electroporation patches, which have miniaturized electrodes and built-in dose control and control units, which are housed within the patch. The method has especially been used successfully in transdermal delivery of DNA vaccines, insulin, and drugs made of peptides.

Taken together, the above approaches constitute the leading edge of energy-assisted transdermal delivery technologies that facilitate rapid on-demand delivery and fine control of therapeutic agents and an increased range of targets of biologically complex molecules.

7.3.2 Safety, Efficacy, and Clinical Applications of Physical Enhancement Techniques

The successful application of physical enhancement methods depends on balancing permeation efficiency with patient safety and comfort. Since these techniques alter the skin barrier through mechanical, thermal, or electrical means, ensuring biocompatibility and reversible effects is essential.

• Safety Considerations:

Modern devices are engineered with strict control over parameters such as temperature, voltage, and exposure time to minimize pain and prevent tissue damage. For instance, thermal ablation systems are calibrated to generate microchannels confined to the uppermost layers of the skin, ensuring no damage to underlying dermal tissues. Similarly, electroporation systems now use low-voltage, high-frequency pulses to reduce discomfort while maintaining efficacy. Continuous monitoring of skin impedance and temperature during treatment helps ensure procedural safety.

• Efficacy and Clinical Applications:

Such physical techniques have a considerable effect on increasing the bioavailability and the onset of action of the drug in transdermal delivery.

·       Vaccine delivery has been studied thoroughly with thermal ablation which provides needle-free delivery of vaccines with enhanced antigen stability.

·       Sonophoresis has succeeded in pain management systems, which maximizes the skin permeation of nonsteroidal anti-inflammatory medications (NSAIDs) and local anesthetics.

·       Gene therapy Because of its capability to carry macromolecules, electroporation is being considered in gene therapy and peptide delivery, including vaccines that are based on DNA and oncolytic therapies.

The technologies have proven to be rapid absorbing and controlled release with high patient acceptability; this has been indicated by clinical trials and preclinical studies. They are powerful contenders in future smart transdermal systems because of this safety, efficacy and multi-functionalities, particularly when biosensors and wireless surveillance are added.

7.4 Case Study: Transdermal Insulin and Hormone Delivery

The clinchest invention of transdermal systems in use of macromolecular and hormonal therapies is considered a revolutionary change in any pharmaceutical and therapeutic innovation. Contrary to traditional methods of drug delivery, including oral pills, injections, infusions, etc., which are typically associated with various disadvantages such as pain, invasiveness, intermittent plasma concentrations, gastrointestinal breakdown, and other active first-pass hepatic cleansing, transdermal systems can offer non-invasive, user-friendly, and physiologically efficacious delivery to the patient. These systems provide a way of releasing drugs in a controlled and sustained manner and provide long-term benefits on the therapeutic effects and minimise the number of doses and enhance general compliance to treatment.

The development of transdermal technology has gone much further than what it was originally designed to do, which was to use small, lipophilic molecules. The recent studies have gone to an extreme with the delivery of macromolecules, including peptides, proteins and hormones which used to be a daunting task as a result of their large molecular size, hydrophilicity, and structural instability. These barriers are currently being surmounted through the development of new delivery mechanisms using the power of novel engineering and material science technologies to increase skin permeability and stabilize fragile biomolecules, as well as to control release kinetics in a safely predictable way.

Insulin and hormonal therapies are some of the most researched and medically imperative applications and can be seen as the embodiment of both the opportunities and the complexity of the field of transdermal delivery. Insulin is a vital peptide hormone that is used to treat diabetes mellitus; it has long been used as a painful injection -it posed a compliance problem and has influenced the quality of life of millions of diabetic patients in the world. To overcome these issues, transdermal insulin delivery attempts to offer painless, sustained, more physiological delivery of insulin by imitating the natural patterns of the body insulin release. Likewise, hormone replacement and contraceptive medications, including estrogen, progesterone and testosterone, can be further enhanced with transdermal delivery characteristics of the assiduous plasma concentrations, less toxicity in the body, and enhanced metabolic stabilization in comparison with oral or injectable administration.

Newer developments in microneedle technology, iontophoresis, sonophoresis, electroporation and nanocarrier-based preparation have provided the opportunity to overcome the imposing barrier presented by stratum corneum. These approaches improve macromolecular drug delivery into the systemic circulation in a safe and temporary manner, increasing skin permeability. Moreover, recent technical advances embodied in the form of smart patches in integration with biosensors and Internet of Things (IoT) technology have transformed the field of therapeutic monitoring and custom delivery of drugs, which in turn include real-time feedback, adaptive dosage control, and better entertainment.

All these inventions are transforming the frontiers of transdermal therapy to a position where there is a balance between drug effectiveness and comfort to the patient. The given case studies on insulin and hormone transdermal delivery help to understand that the innovation technologies are utilised to develop safer, smarter and more effective systems that can transform the chronic disease management, endocrine treatment into really patient-centered, precision-based interventions.

7.4.1 Transdermal Insulin Delivery: Challenges and Emerging Solutions

Developing non-invasive methods of injections is a subject of intense focus in contemporary pharmaceutical studies due to the many constraints linked to traditional subcutaneous injections. Although injections are the usual practice in the treatment of diabetes, they have a number of disadvantages: they hurt the patients, they cause an infection in the area of injection, they lead to lipohypertrophy of the injection site due to repeated injections within long intervals, and they decrease patient compliance, especially individuals who need to inject using multiple injections daily. These difficulties have led to the use of alternative delivery routes that have been painless, convenient, and have the ability of providing stable glycemic control.

Transdermal insulin delivery is an opportunity, but it is faced with significant inherent challenges. Insulin belongs to the group of macromolecular peptides, i.e., it contains 5.8 kDa of molecular weight and is a hydrophilic compound, which constitutes a grave impairment of passive diffusion rates across the skin, most especially, the stratum corneum. This stratum is an extremely dense layer which consists of tightly packed keratinocytes covered with an lipid matrix and as a result of which insulin cannot be delivered to the body by conventional transdermal methods because of its large size (more than 500 Da) and solubility in water in the body.

In order to address these issues, a range of improvement measures have been considered, and the methods that will help to temporarily make the skin more permeable and help insulin penetrate it without causing harm or discomfort to the patients have been considered. Nevertheless, the use of microchannels formed across the stratum corneum of the skin (microneedle arrays); transient electrical currents of low level through the skin (iontophoresis); encapsulation of insulin within liposomes, polymeric nanoparticles or other vesicle systems (nanocarrier-based formulations) has all demonstrated potential. These methods facilitate not only transdermal absorption but also controlled release, lower dose frequency, and better pharmacokinetic characteristics to get the dream of a genuinely patient-friendly insulin delivery system even nearer to the truth.

Moreover, precision of transdermal insulin therapy can be improved with the help of smart patch technologies and biosensors as their implementation will make it possible to measure glucose levels and provide adaptive releases of insulin to assist in the management of diabetes on a personalized, automated, and non-invasive basis.

·       Challenges in Transdermal Insulin Transport

The corneous layer (last layer of the epidermis) is referred to as the stratum corneum and constitutes thickly packed and keratinized cells embedded within a fine and well-organised lipid structure, commonly known as a brick-and-mortar structure. This structure acts as the major impediment barrier of the skin and therefore inhibited the entry of the majority of the exogenous molecules. This barrier is especially a formidable one in the case of the large macromolecules such as insulin, with its molecular weight of around 5.8 kDa. The compact pattern of intercellular lipids severely restricts passive diffusion thus making conventional transdermal delivery ineffective to reach clinically substantial plasma levels.

The bio chemistry of insulin also makes transdermal delivery more difficult in addition to its size. The peptide is very vulnerable to denaturation or degradation in unfavorable conditions, such as changes of temperature, changes of pH, enzymatic activity in the skin and in the formulation environment. In the absence of protective approaches, the insulin molecules can experience loss of their structural stability and biological functions and considerably lower the therapeutic efficacy.

This means that the attainment of therapeutic plasma concentration of insulin by the traditional passive transdermal systems is very inconvenient. Microarrays of needles, iontophoresis, sonophoresis and encapsulation of nanocarriers are necessary to surmount these drawbacks. The approaches disrupt the stratum corneum temporarily, active transport, or shield the molecule against degradation and make insulin achieving an efficient delivery and safe with minimal harm to the biological activity. Through the combination of these state-of-the-art methods, scientists want to see the shift in the insulin therapy concept into non-invasive transdermal platforms that patients will be able to use to gain control and regulate their glucose levels on a consistent and controlled basis.

·       Emerging Technological Solutions

The new studies in the field of transdermal drug delivery have been related to the emerging active methods and nanocarrier-based methods which consider the inherent difficulties of transporting the macromolecular drugs such as insulin and other therapeutic peptides. There are barriers to traditional passive diffusion as stratum corneum barrier and physicochemical characteristics of large, hydrophilic drugs, resulting in a lack of ability to reach therapeutic plasma concentrations. Active improvement techniques have been solved to counter such barriers such as microneedles, iontophoresis, sonophoresis and electroporation. The mechanisms work by temporarily disrupting or circumventing the stratum corneum and establishing routes of entry of macromolecules into the skin and avoiding tissue destruction or apoptosis.

Simultaneously, liposomes, niosomes, polymeric nanoparticles and solid lipid nanoparticles have developed into potent systems of nanocarrier delivery to enhance transdermal drug delivery. Such nanoscale carriers have the capability of encapsulating sensitive biomolecules, preserving them against enzymatic degradation and stress, and increasing their solubility and stability, as well as bearing controlled release. Targeted delivery Nanocarriers can be designed to target delivery of the drug to select layers of the skin or enter into a system with better pharmacokinetics.

With the combination of such active and nanotechnology-based strategies, it is now possible to achieve the modern transformation of transdermal systems that works effectively in the delivery of macromolecules that have been traditionally viewed as not suitable to be applied to the skin. Not only does this convergence of technologies increase drug permeability and therapeutic efficacy, but it also reduces the dose frequency, side effects of all doses to the system, and offers patient adherence, which is a much-needed pathway in patient-centric and non-invasive-delivery drug delivery platforms:

• Microneedle-Assisted Insulin Delivery:

Micro needles have become an innovative product in the field of transdermal insulin administration by offering a low intervention mechanism to overcome the most difficult obstacle of the stratum corneum. The length of these microscopic projections, which are normally between 100 and 1000 micrometers, form temporary microchannels in the epidermis or dermis, which does not touch the end of pain-receptive nerve endings, thus making the procedure painless and tolerable by them. Micro needle penetration in the skin only to the superficial layers enables insulin to diffuse directly to the dermal interstitial fluid, which can gain entry into the systemic circulation quite effectively, thus resulting in a fast action initiation and controlled pharmacokinetics.

Dissolving microneedles and hydrogel-forming microneedles are two main types of microneedles considered in insulin delivery. The microneedles wherein the insulin is entraped inside the needle are prepared by dissolved, water soluble polymer which is biocompatible in nature. When inserted into the skin, the needles break up slowly to discharge insulin into the blood in a slow and controlled way. Micro-needles that form a hydrogel, however, take up interstitial fluid and become swollen to create a continuous channel to allow permanent diffusion of insulin through an external drug reservoir. The benefits of both systems are specific dosing, sustained or programmable release profiles, and decreased risk of infection, which happens as the microchannels naturally go closed following their removal, eliminating the fears that come with repeating the use of a needle.

Micro needle insulin patches have proven to be effective and safe with preclinical research and clinical trials finding that these type of insulin patches effectively glycemic control in comparison to traditional subcutaneous injection of insulin, and are even better than its traditional form. According to the reports of patients, these systems provide high levels of comfort and acceptance because enduring the pain is painless and the amount of pain is self-administered, which is useful especially in the pediatrics, older patients, and needle-phobic patients. In addition, microneedle patches can be easily modified to be integrated with smart devices (or glucose sensors) to create closed-loop insulin delivery systems, which react to real-time glucose levels, which is an important step towards patient-centric management of diabetes.

To conclude, microneedle is a safe, effective and patient friendly device which integrates minimally invasive insulin delivery with precise pharmacokinetic control, enhanced adherence and the possibility of incorporation with sophisticated monitoring methods, and is therefore among the most promising in transdermal macromolecular therapy.

• Iontophoresis and Electroporation:

Iontophoresis and electroporation are the modern active methods of the transdermal enhancement, which offers a controlled, accurate delivery of insulin in overcoming the obstacle of the stratum corneum diffusion.

Itonophoriesis is a process that is used to move charged insulin molecules to deeper layers of the skin by the use of low-intensity electrical current. The method relies on the electromigration principle, according to which similarly charged ions are repelled out of the electrode into the skin, and the electroosmosis principle, according to which transport of some solvents as a result of the current can help in transporting drugs. This procedure enables the dose, and rate of insulin delivery to be programmably controlled, thus individual needs of the patient can be adjusted to therapeutic purposes. Ionophoresis also allows on-demand delivery of insulin, in which timing and dose of the drug may be changed in real-time, which may be in conjunction with continuous glucose monitors. It has been demonstrated that iontophoresis could improve insulin permeation in a significant manner without altering its biological activity, to offer an alternative to the invasive method of subcutaneous injection.

Electroporation is an alternative form that involves the treatment of the lipid-bilayers of the stratum corneum with short-high-voltage pulses of electricity to create temporary micro- or nano-sized holes. These pores enable resonant and prompt movement of big sizable molecules like insulin that would have not otherwise been in a position to pass through the skin barrier. The volatile nature of these pores can be used to make sure that the skin barrier is repaired shortly after treatment to reduce the possibility of irritation or infection. Electroporation can also be combined with sensor-based systems to achieve automated, responsive delivery of insulin as well as when the action needs to occur quickly, e.g., postprandial glucose regulation.

Iontophoresis and electroporation have a number of important benefits over conventional delivery of insulin, namely they are both non-invasive, controllable in expression, and potentially can be combined with smart glucose biosensors. These techniques could lead to better glycemic management, enhance patient adherence and decrease the burden of the frequently used injections, which means that they will be the future of the next generation of diabetes management interventions.

• Nanocarrier-Based Insulin Systems:

Nanotechnology provides a good alternative that could merit these inherent limitations to transdermal insulin delivery which include molecular mass, solubility, and degradation by enzymes. Different forms of nanoparticles such as liposomes, solid lipid nanoparticles (SLNs) and polymeric nanocarriers have been developed to entrap insulin against thermal, pH, and enzymatic instability during its delivery across the skin. These nanopores promote the solubility, stability and permeability of the drug which allows the drug to be better absorbed in the dermis and systemic circulation.

The liposomes or phospholipid bilayers have the ability to package both; phospholipic and lipophilic drugs, and allow controlled and long-lasting delivery of insulin. Solid lipid nanoparticles are a mix of polymeric system with lipid-based carrier with enhanced stability and prolonged circulation in the body as well as protection against enzyme degradation. Polymeric nanocarriers, which occur due to using a variety of materials, e.g., PLGA or chitosan, can be surface functionalized by using targeting ligands or glucose-sensitive polymers and allow smart, responsive insulin delivery in response to alterations in blood glucose.

Other developed nanocarrier systems incorporate glucose-sensitive compounds including phenylboronic acid derivatives or enzyme-based systems, which respond to hyperglycemic states and release insulin independently. This would be a major advancement toward close loop delivery systems of insulin, which are fully self-regulated and would not require regular checks and manual insulin injections.

In general, microneedle array, electrical betterment methods (iontophoresis and electroporation), and nanocarrier combined systems are changing the way insulin is being treated. These technologies make it possible to conduct non-invasive, pain-free, and adaptive transdermal delivery, enhance adherence, glycemic control, and quality of life in patients. Combining the transdermal devices with both smart sensing and responsive solutions, the future of diabetes treatment is shifting towards digitally interconnected, patient-centered treatment that will reduce pain and create more precise therapy.

7.4.2 Hormone Delivery Systems: Advances in Estrogen, Testosterone, and Contraceptive Patches

Transdermal systems offer benefits of consistency, controlled, non-invasive delivery of endocrine-active molecules that are unique to hormone therapy preparation, compared to oral or injectable formulations. Conventional oral delivery regularly exposes hormone to the hepatic first-pass metabolism, resulting in high inter-subject bioavailability and extensive peaks and declines in plasma concentration. Conversely, transdermal delivery enables hormones to avoid entering the gastrointestinal tract and liver, which leads to a more stable systemic level, lower rate of metabolic degradation, and greater treatment rates.

Estragen, progesterone, and also testosterone are some of the hormones that can be administered through transdermal application because they are small molecules, moderate lipophilic, and are capable of diffusing through the stratum corneum. These properties allow efficient absorption by the skin and deliver into systemic circulation, and can bear physiologically pertinent concentrations during prolonged time.

Advantages of Transdermal Hormone Delivery

• Stable PlasmaLevels: Helps reduce the destructive changes in hormones that occur with peak dosing and therefore decreases the side effects of peak dosing, including nausea, mood swings or cardiovascular difficulties.
• Enhanced Compliance of patients: Non-invasive delivery through patches or gel decreases discomfort, inconvenience and anxiety associated with injections or being required to take multiple pills daily.
• Controlled and Specific Release: Within the framework of an administration once a day, once a week, and even once a month, it may be possible to design a formulation with a specific amount of drugs, matrix system, or nanocarrier integration.
• Less Hepatic Load: transdermal hormones: transdermal hormones do not undergo first-pass metabolism; therefore, they can be administered at lower doses, lessening the risk of liver toxicity or side effects caused by metabolites.

Formulation Approaches

1. Transdermal Patches: Hormone releasing patches are produced through the design of adhesive patches that adhere to the skin and are capable of constant release of drugs through a reservoir or matrix design. An example is estradiol patches used as constant estrogen replacement during menopausal therapy and testosterone patches used to keep physiological levels of androgen in hypogonadal men.
2. Nano-Carrier Systems: Incorporation of hormones into liposomes, niosomes, or polymeric nanoparticles may improve the solubility, stability, and controlled release, and may permit site-specific delivery.
3. Hydrogel and Gel Formulations: Semi-solid hormone preparations are good assurances of homogeneous distributions, fast absorption, and flexibility of dosing, commonly with progesterone or testosterone gels.

·       Clinical Impact

Transdermal hormone delivery has played a major role in the treatment of menopause, andropause, contraceptives and endocrine disorders. These systems improve the efficacy and quality of life by stabilizing plasma concentrations, decreasing the frequency of dosage, and improving patient compliance. Besides, novel nanocarrier-based and improved patch systems are opening the path to intelligent responsive hormone delivery systems, which can perhaps be programmed to respond to physiological feedback by adjusting their release rate.

·       Transdermal Estrogen and Testosterone Systems

Estrogen Patches:

The transdermal estrogen patches has turned into a standard of having menopausal hormone replacement therapy (HRT) since its use can stabilize the levels of systemic estrogens without peaks and troughs of oral HT. The oral estrogens are mainly metabolized in the liver by the first pass and therefore may cause the clotting factors to increase and this causes cardiovascular effects as well as hepatic overload and change in lipid metabolism. Transdermal patches enable the direct delivery of the estrogen through the skin, avoiding hepatic loads and reducing the number of associated complications.

Modern estrogen patches have matrix based designs where the hormone is uniformly distributed throughout a polymeric structure where the hormone can be released in a controlled time of 24 or more hours. Manufacturing of the adhesive systems is done in such a manner that the adhesives adhere to the skin in a similar manner with a high degree of consistency that guarantees good absorption and low irritation. Moreover, there are patches that include permeation enhancers to simplify passage through the stratum corneum without traumatizing the barrier to the skin. The clinical literature has proven that transdermal estrogen therapy is an effective treatment in treating vasomotor symptoms, bone loss prevention and generally uplifting the quality of life in menopausal women with a desirable safety profile.

Testosterone Patches:

The testosterone replacement therapy is important in men with hypogonadism as it helps them to normalize androgen levels enabling them to maintain muscle mass, bone density, libido, and general metabolic performance. Transdermal testosterone patches deliver a controlled and sustained release which is very similar to the natural circadian cycle of testosterone secretion that takes place within the body and normally peaks in the early morning hours and subsequently drops over the day.

Patch designs built in the form of a matrix promote homogeneous distribution of drug over the skin surface which allows predictable pharmacokinetics and eliminates a variation in plasma testosterone response. Transdermal testosterone has a lower possibility of liver toxicity and other system complications by circumventing the gastrointestinal tract and hepatic metabolism as the active compound. Moreover, modern patches are composed so as to be adhesive and breathable and comfortable to the skin, which minimizes chances of irritation, redness or allergic response.

Advantages of Modern Transdermal Hormone Patches:

• Steady Therapeutic Levels: Maintain consistent plasma hormone concentrations, reducing the risk of side effects associated with peak dosing.
• Improved Patient Compliance: Once-daily or multi-day application simplifies therapy, especially for chronic conditions.
• Reduced Systemic and Hepatic Side Effects: Bypassing the liver decreases the likelihood of hepatotoxicity and cardiovascular risks.
• Enhanced Formulation Performance: Matrix systems and permeation enhancers improve absorption efficiency and minimize skin irritation.

On the whole, transdermal patches as a method of hormone therapy have become a landmark of hormone therapy allowing safe delivery of hormones, convenient and physiologically relevant and increasing the efficacy and patient compliance, reducing the risks of hormone introduction that are inherent to the use of oral and injectable hormones.

Contraceptive and Combination Hormone Patches

Transdermal contraceptive patches in reproductive health As an adjunct to oral contraceptives, they offer convenience, better adherence and reliability making them a popular alternative in contraceptive use. These patches usually contain estrogen and progestin and they are installed once every seven days so that there should be a constant supply of the hormones within seven days and the hormones will be supplied in a constant amount and it will not be necessary to take the pills every day. This simplified protocol minimizes the chances of omitted doses that is usually a major issue with oral contraceptives and will offer the provision of consistent plasma hormone levels, which increases the contraceptive effects.

The patches are acted by the hormones that are transported through stratum corneum and into the systemic circulation bypassing the gastrointestinal tract and the hepatic first-pass metabolism, minimizing the changes in hormone levels and alleviating possible hepatic side effects. The patch designs today are using matrix systems or reservoir designs which guarantee equal drug delivery and reliable pharmacokinetics and the adhesive polymers hold the patch firmly against the skin but are not irritating to such an extent. It has been determined through clinical research that these patches are very effective in preventing ovulation, menstrual regulation, and offer other advantages of less menstrual pain and premenstrual syndrome symptoms.

Nanocarrier-Based Hormone Delivery:

Most recent developments in nanotechnology have improved even more on the transdermal delivery of hormones. Overcoming the barrier properties of the skin which is an inherent environment is being done through the use of nanocarriers e.g. liposomes, nanoemulsions, solid lipid nanoparticles, and polymeric nanoparticles which shield sensitive hormonal compounds against degradation. The following are the advantages of these nanoscale systems:

• Increased Penetration by the skin: The low size and adjustable surface characteristics of nanocarriers permit heightened penetration through the stratum corneum enabling the delivery of lipophilic and hydrophilic hormones.
• Protection against Degradation: The hormones are protected as the Degradation by enzymes and other chemical environments will be prevented by the encapsulation of the hormone, preserves structural integrity, and bioactivity across transdermal delivery.
• Controlled and Sustained Release: Nanocarriers may be designed in a manner to deliver hormones to the body in a controlled manner, or upon reaction to a specific stimulus, maintaining enduring plasma concentrations.
• Dual-Drug Incorporation: More complex nanocarrier delivery systems can combine estrogen and progestin or other therapeutic combinations that can release together with a profile and eliminating the necessity to use more than one patch or formulations.

Clinical and Therapeutic Implications:

The combination of transdermal contraception patches that are used on a weekly basis and innovative nanocarrier technology is a significant improvement in reproductive health care. These systems may enhance patient adherence by means of the convenience provided with once-weekly dosing and accuracy provided through nanocarrier-mediated delivery, which studies have reported is a significant barrier to patient adherence to daily oral contraceptive use. Nanocarriers, e.g. liposomes, polymeric nanoparticles, nanoemulsions, shield sensitive hormone compounds against degradation, facilitate the enhancement of skin penetration and controlled sustained release, so that the level of hormones is kept steady throughout the dosing time. Not only does this constant delivery maximise the contraceptive effect, but also reduces cardiac systemic side effects (a common feature with oral or injectable delivery methods) in the form of changes in estrogen and progestin levels.

In addition, these patch-based nanocarrier-assisted patches open the door to customized contraceptive treatment, in which the rate, proportion and dose levels of drugs delivered can be adjusted to fit a specific physiological profile, lifestyle or hormonal needs. This technology is in line with the general trend of precision medicine related to reproductive health that offers safer, more effective, and patient-centric reproductive methods of contraception. Nano carrier patches remain a game changer in the current hormone delivery system by its ability to combine efficacy with safety and convenience, which has enhanced clinical and quality of life in patients taking hormones.

Clinical Effectiveness and Patient Compliance

The evidence provided by clinical practices has continued to show that transdermal hormone patches have been found to be very effective in ensuring stable plasma levels of hormones effectively preventing the highs and lows present in oral or injected hormone therapies. These changes in hormone concentrations may lead to the unwanted affect such as nausea, mood swings, headache, and, in other circumstances, cardiovascular stress. Transdermal patches offer more predictable and stable pharmacological effects with the continual has a controlled release of hormones, meaning that therapeutic levels will be attained throughout longer periods. This consistent uptake is especially useful in long-term hormone treatment i.e. menopausal hormone replacement therapy (HRT) or testosterone supplementation in men with a hypogonadal adenocrine hypothalamus as in such cases, constant hormone exposure is needed to control the symptoms as well as physiological regulation.

The clinical utility of transdermal patches is further associated with the non-invasive and easy to use design. The self-administration method of patches ensures patients are not exposed to adverse conditions of needles and inoculations that cause needlestick infections, anxiety, and pain, which leads to them sustaining the therapy significantly better. Besides, the unobtrusive and convenient process of patches are useful in the daily activities of life without disruption which is essential in handling chronic conditions that involving long-term hormone replacement product use.

The recent development of technology has led to bioresponsive temperature sensitive patches, a great breakthrough in accurate delivery of hormones. These intelligent systems can detect physiological signals, such as skin temperature, the pH or the chemical input of hormones, and modify the rate of hormone discharge. An example of this is that the patches might be programmed to become more active at the times when hormones are normally more active (that is, due to the circadian peak), and replicates natural hormone rhythms. This strategy promotes the efficacy of therapy by synchronizing the delivery with the body rhythms in addition to decreasing unneeded systemic exposure, limiting the risk of causing side effects and ensuring great safety.

Moreover, combining patches with new polymeric matrices, nanocarriers, or syncing with micro-reservoir technologies increases patches to release hormones in several days or even weeks and brings together convenience and high precision. There are also systems of some level of advancement of the hormone therapy that facilitates the personal hormone therapy, drug release kinetics and doses are provided to individual patient profile, levels of hormone or lifestyle. All of these represent how the innovation of transdermal hormone delivery systems is transforming the primitive patches to smart and patient-centric therapeutic platforms, enabling superior efficacy, safety and compliance and laying the groundwork of the future generation of adaptive and personalized hormone therapies.

REFERENCES

1.     Sahu, A., Mishra, S., Wal, P., Debnath, B., Chouhan, D., Gunjal, S. D., & Tripathi, A. K. (2024). Novel Quinoline‐Based RAF Inhibitors: A Comprehensive Review on Synthesis, SAR and Molecular Docking Studies. ChemistrySelect, 9(23), e202400347.

2.     Tripathi, A. K., Soni, R., & Verma, S. (2022). A review on ethnopharmacological applications, pharmacological activities, and bioactive compounds of Mimosa pudica (linn.). Research Journal of Pharmacy and Technology, 15(9), 4293-4299.

3.     Sinha, S., Tripathi, A. K., Pandey, A., Naik, P., Pandey, A., & Verma, V. S. (2024). Self-assembled PEGylated micelles for precise and targeted drug delivery: Current challenges and future directions. Biocatalysis and Agricultural Biotechnology, 60, 103296.

4.     Mishra, S., Grewal, J., Wal, P., Bhivshet, G. U., Tripathi, A. K., & Walia, V. (2024). Therapeutic potential of vasopressin in the treatment of neurological disorders. Peptides, 174, 171166.

5.     Koliqi, R., Fathima, A., Tripathi, A. K., Sohi, N., Jesudasan, R. E., & Mahapatra, C. (2023). Innovative and Effective Machine Learning-Based Method to Analyze Alcoholic Brain Activity with Nonlinear Dynamics and Electroencephalography Data. SN Computer Science, 5(1), 113.

6.     Tripathi, A. K., Dwivedi, C. P., Bansal, P., Pradhan, D. K., Parganiha, R., & Sahu, D. (2022). An Ethnoveterinary Important Plant Terminalia Arjuna. International Journal of Health Sciences, (II), 10601-10607.

7.     Habeeb, M., Vengateswaran, H. T., Tripathi, A. K., Kumbhar, S. T., You, H. W., & Hariyadi. (2024). Enhancing biomedical imaging: the role of nanoparticle-based contrast agents. Biomedical Microdevices, 26(4), 42.

8.     Singh, K., Jain, D., Sethi, P., Gupta, J. K., Tripathi, A. K., Kumar, S., ... & Guru, A. (2024). Emerging pharmacological approaches for Huntington's disease. European Journal of Pharmacology, 980, 176873.

9.     Babbar, R., Kaur, A., Vanya, Arora, R., Gupta, J. K., Wal, P., ... & Behl, T. (2024). Impact of bioactive compounds in the management of various inflammatory diseases. Current Pharmaceutical Design, 30(24), 1880-1893.

10.  Tripathi, A. K., Sharma, N., Mishra, J., Bisoi, D., Mohapatra, N., Muztaba, M. M., ... & TarakaRamarao, C. (2023). Evaluation Of Anti–Inflammatory Activity Of Plant Extract Of Cordia Dichotoma Leaves On Carrageenan-Induced Paw Edema In Albino Wister Rats And Its Phytochemical Analysis. Ann. For. Res, 66(1), 803-818.

11.  Gupta, J., Kumar, D., Gupta, R., Diwakar, D., Shanno, K., Tripathi, A. K., ... & Kumar, M. (2025). Therapeutic Potential of Traditional Chinese Medicine loaded Nanocarriers in Wound Management: Current Status and their Future Perspective. Pharmacological Research-Modern Chinese Medicine, 100622.

12.  Tripathi, A. K. Toxicity Evaluation of Textile Effluents on Gill Morphology and Enzyme Activity in Zebrafish.

13.  Singh, B., Mahmood, A. A. R., Semwal, B. C., Dewangan, H. K., Alam, P., & Tripathi, A. K. (2025). Encapsulation of lysozyme in hybrid vesicles to protect from thermal challenges. International Journal of Biological Macromolecules, 312, 143603.

14.  Prabagar, J. S., Ashajyothi, C., Tripathi, A. K., Makgwane, P. R., Rasool, A., Alqarni, M. H., ... & Shivaraju, H. P. (2025). Synergistic effects of Ag/gC 3 N 4-incorporated bi-metallic ZnTi-LDH in CO 2 photoreduction to hydrocarbons. Materials Advances.

15.  Raj, R., Tripathi, A. K., Saranya, P., Pal, R. S., Singh, K., Jain, D., ... & Kumar, S. (2024). A review of molecular investigations on traditional Chinese medicinal plant-based therapies in multidrug-resistant tuberculosis. Pharmacological Research-Modern Chinese Medicine, 13, 100521.

16.  Tripathi, A. K. A text book of pathophysiology. NEXUS KNOWLEDGE PUBLICATION.

17.  Dwivedi, J., Wal, P., Wagh, V. D., Sachan, P., Joshi, N. S., Goyal, S., & Tripathi, A. K. (2025). Paederia Foetida Linn (Rubiaceae): Chemical Diversity, Phytopharmacological Potential, Quantitative Analysis and Clinical Approaches. Combinatorial Chemistry & High Throughput Screening.

18.  Kapil, P., Tripathi, A. K., Pal, R. S., Singh, S. K., Singh, K., Jain, D., & Chaitanya, M. V. N. L. (2025). Therapeutic Potential of Plant Phenolic Acids Combating Cancer Drug Resistance. Recent Advances in Food, Nutrition & Agriculture.